Market Reports Center One Stop Market Reaserch Shop Global Solid Tumors Drugs Market Size, Share, Costs and Price, Global Insights, Trends, Growth, Analysis and Forecasts, 2016-2020 Summary Technavio Announces the Publication of its Research Report – Global Solid Tumors Drugs Market 20162020 Technavio recognizes the following companies as the key players in the global solid tumors drugs market: F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS. Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Advantagene, Agensys, Almac Group, Ambrx, Argos Therapeutics, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, Boehringer Ingelheim, Boston Biomedical, Celldex Therapeutics, Chugai Pharmaceutical, Cold Genesys, CTI BioPharma, Daiichi Sankyo, DNAtrix, Ds-Pharma, Eleison Pharmaceuticals, Eli Lilly, Endo Pharmaceuticals, Formation Biologics, Fortress Biotech, Genmab, GSK, Immatics Biotechnologies, Immunogen, Immunomedics, Intas Pharmaceuticals, Kairos Therapeutics, Kyowa Hakko Kirin, MedImmune, Merck, Mersana Therapeutics, Morphotek, Neovii Biotech, NewLink Genetics, Northwest Biotherapeutics, Novartis, OncoMed Pharmaceuticals, Oxford Biotherapeutics, Peregrine Pharmaceuticals, Polaris Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals, Stemcentrx, Synthon Biopharmaceuticals, TG Therapeutics, and XBiotech. Browse Detail Report With TOC @ https://marketreportscenter.com/reports/316875/global-solid-tumors-drugs-market-2016-2020 Commenting on the report, an analyst from Technavio’ s team said: “A trend which is helping to boost market growth is the emergence of targeted and combination therapies. Targeted and combination therapies are being increasingly developed to treat solid tumors. Targeted therapies, which exploit the Market Reports Center One Stop Market Reaserch Shop surface markers or properties of diseased or infected cells, cause fewer adverse effects than conventional non-targeted therapies. For example, in 20% of the cases, breast cancer is associated with the overexpression of HER2, wherein drugs such as Kadcyla and Herceptin are administered as monotherapies or in combination. Targeting multiple pathways are known to reduce the risk of developing treatment-resistant disorders. Thus, combination therapies, which target distinct mechanisms, are highly efficacious in treating solid tumors.” According to the report, a key growth driver which is helping to boost market growth is the exposure to risk factors. Exposure to risk factors for solid tumors and the decrease in practices that reduce this risk are expected to increase the incidence of solid tumors. Solid tumors are associated with modifiable risk factors such as alcohol consumption, physical inactivity, weight gain, and obesity. For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. The consumption of three to six glasses of alcoholic drinks per week can increase the risk of developing the disease by 15%. Also, women with estrogen-positive breast cancer who consume one glass of any alcoholic drink per day have a 90% higher risk of developing second cancer. Further, the report states that one challenge that could hamper market growth is the patent expiration on top-selling drugs. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. About the Solid Tumors Drugs Market The rising prevalence of various cancers, which has led to innovations and technological advancements, drives the development of new immunotherapy drugs that are more effective than the available drugs to treat solid tumors. Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas. Technavio’ s analysts forecast the global solid tumors drugs market to grow at a CAGR of 8.6% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global solid tumors drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat solid tumors. It also considers the revenues to be generated from the sales of drugs that are anticipated to be launched into the market Market Reports Center One Stop Market Reaserch Shop along with the decline in revenues from the patent expiries of the branded drugs during the forecast period. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/316875 Technavio's report, Global Solid Tumors Drugs Market 2016-2020, has been prepared based on an indepth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors • F. Hoffmann-La Roche • Novartis • Celgene • Johnson & Johnson • Pfizer • BMS Other prominent vendors • AbbVie • AbGenomics • ADC Therapeutics • Advantagene • Agensys • Almac Group • Ambrx • Argos Therapeutics • Array BioPharma • Astellas Pharma • AstraZeneca • Bayer • Biogen • Biotech Pharmaceutical • Boehringer Ingelheim • Boston Biomedical • Celldex Therapeutics • Chugai Pharmaceutical Market Reports Center One Stop Market Reaserch Shop • Cold Genesys • CTI BioPharma • Daiichi Sankyo • DNAtrix • Ds-Pharma • Eleison Pharmaceuticals • Eli Lilly • Endo Pharmaceuticals • Formation Biologics • Fortress Biotech • Genmab • GSK • Immatics Biotechnologies • Immunogen • Immunomedics • Intas Pharmaceuticals • Kairos Therapeutics • Kyowa Hakko Kirin • MedImmune • Merck • Mersana Therapeutics • Morphotek • Neovii Biotech • NewLink Genetics • Northwest Biotherapeutics • Novartis • OncoMed Pharmaceuticals • Oxford Biotherapeutics • Peregrine Pharmaceuticals • Polaris Pharmaceuticals • Sanofi • Seattle Genetics • Spectrum Pharmaceuticals • Stemcentrx • Synthon Biopharmaceuticals • TG Therapeutics • XBiotech Market driver • Exposure to risk factors • For a full, detailed list, view our report Market challenge • Patent expiration of top-selling drugs Market Reports Center One Stop Market Reaserch Shop • For a full, detailed list, view our report Market trend • Emergence of targeted and combination therapies • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? To Get Discount On The Report @ https://marketreportscenter.com/request-discount/316875 About Us: Market Reports Centeris an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable. Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies. Contact Information: Sam Collins Market Reports Center 1-646-883-3044 (US) [email protected] https://marketreportscenter.com

Technavio Announces the Publication of its Research Report Global Solid Tumors Drugs Market 2016-2020 Technavio recognizes the following companies as the key players in the global solid tumors drugs market: F. Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, and BMS.